Hagar, a Tel Aviv, Israel-based developer non-invasive continuous glucose monitoring technology that uses RF waves to measure glucose levels in the blood, raised $11.7m in Series B funding.
The round, which brings total funding to $17.1m, following the $4.4m in Series A funding it received in March 2021, was led by a returning investor, Columbia Pacific.
The company intends to use the funds for upcoming trials for Federal Drug Administration (FDA) approval and for completing international patents.
Led by General Guy Zur, CEO, and co-founder, and Br. General Bentzi Gruber, Chairman and Cofounder, Hagar is the developer of GWave, a non-invasive continuous glucose monitoring technology solution that uses RF waves to measure glucose levels in the blood continuously. GWave First Generation is a third of the size of a smartphone, and GWave Second Generation, currently in development, will be a sensor built into a watch the size of a smartwatch that sends glucose readings to the user via a smartphone app that can be shared with their healthcare provider.
The technology was conceived by Dr. Gerry Waintraub.